1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25991
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoss, David M-
dc.contributor.authorThomson, Candice-
dc.contributor.authorHamad, Nada-
dc.contributor.authorLane, Steven W-
dc.contributor.authorManos, Kate-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorGuo, Belinda-
dc.contributor.authorErber, Wendy N-
dc.contributor.authorScott, Ashleigh-
dc.contributor.authorViiala, Nick-
dc.contributor.authorChee, Lynette-
dc.contributor.authorLatimer, Maya-
dc.contributor.authorTate, Courtney-
dc.contributor.authorGrove, Carolyn-
dc.contributor.authorPerkins, Andrew C-
dc.contributor.authorBlombery, Piers-
dc.date2021-03-02-
dc.date.accessioned2021-03-09T05:02:01Z-
dc.date.available2021-03-09T05:02:01Z-
dc.date.issued2021-03-02-
dc.identifier.citationPathology 2021; online first: 2 Marchen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/25991-
dc.description.abstractMyeloproliferative neoplasms are characterised by somatic mutations in pathways that regulate cell proliferation, epigenetic modifications, RNA splicing or DNA repair. Assessment of the mutational profile assists diagnosis and classification, but also aids assessment of prognosis, and may guide the use of emerging targeted therapies. The most practical way to provide information on numerous genetic variants is by using massively parallel sequencing, commonly in the form of disease specific next generation sequencing (NGS) panels. This review summarises the diagnostic and prognostic value of somatic mutation testing in Philadelphia-negative myeloproliferative neoplasms: polycythaemia vera, essential thrombocythaemia, primary myelofibrosis, chronic neutrophilic leukaemia, systemic mastocytosis, and chronic eosinophilic leukaemia. NGS panel testing is increasing in routine practice and promises to improve the accuracy and efficiency of pathological diagnosis and prognosis.en
dc.language.isoeng
dc.subjectMyeloproliferative neoplasmsen
dc.subjectPCRen
dc.subjectdiagnosisen
dc.subjectmutationsen
dc.subjectprognosisen
dc.titleMyeloid somatic mutation panel testing in myeloproliferative neoplasms.en
dc.typeJournal Articleen
dc.identifier.journaltitlePathologyen
dc.identifier.affiliationDepartment of Haematology and Genetic Pathology, Flinders University and Medical Centre, Adelaide, SA, Australiaen
dc.identifier.affiliationHaematology Department, Sir Charles Gairdner Hospital, Perth, WA, Australiaen
dc.identifier.affiliationCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australiaen
dc.identifier.affiliationClinical Haematologyen
dc.identifier.affiliationMyeloproliferative Neoplasms Working Party, Australasian Leukaemia and Lymphoma Group, Melbourne, Vic, Australiaen
dc.identifier.affiliationDepartment of Haematology, Alfred Hospital, Monash University, Melbourne, Vic, Australiaen
dc.identifier.affiliationDepartment of Clinical Haematology, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Department of Medicine, The University of Melbourne, Melbourne, Vic, Australiaen
dc.identifier.affiliationDepartment of Haematology and Bone Marrow Transplantation, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australiaen
dc.identifier.affiliationHaematology Department, St Vincent's Hospital, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australiaen
dc.identifier.affiliationDepartment of Haematology and Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australiaen
dc.identifier.affiliationQIMR Berghofer Medical Research Institute, University of Queensland, Brisbane, Qld, Australiaen
dc.identifier.affiliationSchool of Biomedical Sciences, University of Western Australia, Perth, WA, Australiaen
dc.identifier.affiliationHaematology Department, PathWest Laboratory Medicine, Perth, WA, Australiaen
dc.identifier.affiliationDepartment of Haematology, Liverpool Hospital, University of New South Wales, Sydney, NSW, Australiaen
dc.identifier.affiliationACT Pathology and Canberra Hospital, Australian National University, Canberra, ACT, Australiaen
dc.identifier.affiliationHaematology Department, Gold Coast University Hospital, University of Queensland, Southport, Qld, Australiaen
dc.identifier.doi10.1016/j.pathol.2021.01.003en
dc.type.contentTexten
dc.identifier.pubmedid33674147
local.name.researcherGrigg, Andrew P
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

48
checked on Nov 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.